




FIG. 1A




FIG. 1B

Antibody	T47D	
	COSMC-KO	T47D
2D5.2F6.2C11		
5B8.2A11.2C7		
15F3.2D11.1E6		




FIG. 1C




FIG. 1D

Antibody	T47D	
	COSMC-KO	T47D
2D5.2F6.2C11	●	○
5B8.2A11.2C7	■	□
15F3.2D11.1E6	▲	△




FIG. 1E




FIG. 2




FIG. 3A

Pancreatic Cancer (TMA PA241d)

Antibody	Cases	Positive	Negative
2D5.2F6.2C11	6	3 (50%)	3 (50%)
5B8.2A11.2C7	6	3 (50%)	3 (50%)
15F3.2D11.1E6	6	3 (50%)	3 (50%)
Anti-MUC4	6	3 (50%)	3 (50%)

FIG. 3B




FIG. 3C

7/15




FIG. 3D





FIG. 3E



TMA BCN721B
FIG. 3F




FIG. 3G




FIG. 4A




FIG. 4B

10/15




FIG. 4C

11/15

FIG. 5A




FIG. 5B





FIG. 6



Long HC MUC4(2D5)- GP/CD3	mVH-MUC4- GP	hCH1	Linker 1	hVH-CD3 Roche	Linker 2	hCL-kappa (mut)	Linker 3	hCH2 mut	hCH3 (long)	CHS
Short HC MUC4(2D5)-GP	mVH-MUC4- GP	hCH1	Hinge 1	hCH2 mut	hCH3 (short)	CHS				
Cross VL CD3	hVL-lambda- CD3	Linker 4	hCH1	Hinge 2						
VL kappa MUC4(2D5)-GP	mVL-kappa- MUC4-GP	hCL-kappa								

FIG. 7

13/15




FIG. 8

14/15

*Killing of MCF2 cells by 2D5 2+1 CrossMAb
CD4+ T cells: 5:1 E:T ratio*




FIG. 9A

*Killing of HCT116 (COSMC-KO) by 2D5 2+1
CrossMAb PBMCs: 10:1 E:T ratio*




FIG. 9B

15/15




FIG. 10